A multicenter randomized controlled trial of medium-chain triglyceride dietary supplementation on epilepsy in dogs.
antiepileptic drug
antiseizure
canine
ketogenic diet
nutrition
refractory epilepsy
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
27
06
2019
accepted:
12
03
2020
pubmed:
16
4
2020
medline:
26
1
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
Medium-chain triglyceride (MCT) enriched diet has a positive effect on seizure control and behavior in some dogs with idiopathic epilepsy (IE). To evaluate the short-term efficacy of MCTs administered as an add-on dietary supplement (DS) to a variable base diet to assess seizure control and antiseizure drug's (ASD) adverse effect profiles. Twenty-eight dogs with International Veterinary Epilepsy Task Force Tier II (IVETF) level diagnosis of treated IE with 3 or more seizures in the last 3 months were used. A 6-month multicenter, prospective, randomized, double-blinded, placebo-controlled crossover trial was completed, comparing an MCT-DS with a control-DS. A 9% metabolic energy-based amount of MCT or control oil was supplemented to the dogs' diet for 3 months, followed by a control oil or MCT for another 3 months, respectively. Dogs enrolled in this study satisfied most requirements of IE diagnosis stated by the IVETF II level. If they received an oil DS or drugs that could influence the metabolism of the investigated DS or chronic ASD, the chronic ASD medication was adjusted, or other causes of epilepsy were found, the dogs were excluded from the study. Seizure frequency (median 2.51/month [0-6.67] versus 2.67/month [0-10.45]; P = .02) and seizure-day frequency were significantly (1.68/month [0-5.60] versus 1.99/month [0-7.42], P = .01) lower when dogs were fed MCT-DS in comparison with the control-DS. Two dogs were free of seizures, 3 had ≥50% and 12 had <50% reductions in seizure frequency, and 11 dogs showed no change or an increase in seizure frequency. These data show antiseizure properties of an MCT-DS compared to a control oil and support former evidence for the efficacy of MCTs as a nutritive, management option for a subpopulation of drug-resistant dogs with epilepsy.
Sections du résumé
BACKGROUND
BACKGROUND
Medium-chain triglyceride (MCT) enriched diet has a positive effect on seizure control and behavior in some dogs with idiopathic epilepsy (IE).
OBJECTIVE
OBJECTIVE
To evaluate the short-term efficacy of MCTs administered as an add-on dietary supplement (DS) to a variable base diet to assess seizure control and antiseizure drug's (ASD) adverse effect profiles.
ANIMALS
METHODS
Twenty-eight dogs with International Veterinary Epilepsy Task Force Tier II (IVETF) level diagnosis of treated IE with 3 or more seizures in the last 3 months were used.
METHODS
METHODS
A 6-month multicenter, prospective, randomized, double-blinded, placebo-controlled crossover trial was completed, comparing an MCT-DS with a control-DS. A 9% metabolic energy-based amount of MCT or control oil was supplemented to the dogs' diet for 3 months, followed by a control oil or MCT for another 3 months, respectively. Dogs enrolled in this study satisfied most requirements of IE diagnosis stated by the IVETF II level. If they received an oil DS or drugs that could influence the metabolism of the investigated DS or chronic ASD, the chronic ASD medication was adjusted, or other causes of epilepsy were found, the dogs were excluded from the study.
RESULTS
RESULTS
Seizure frequency (median 2.51/month [0-6.67] versus 2.67/month [0-10.45]; P = .02) and seizure-day frequency were significantly (1.68/month [0-5.60] versus 1.99/month [0-7.42], P = .01) lower when dogs were fed MCT-DS in comparison with the control-DS. Two dogs were free of seizures, 3 had ≥50% and 12 had <50% reductions in seizure frequency, and 11 dogs showed no change or an increase in seizure frequency.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
These data show antiseizure properties of an MCT-DS compared to a control oil and support former evidence for the efficacy of MCTs as a nutritive, management option for a subpopulation of drug-resistant dogs with epilepsy.
Identifiants
pubmed: 32293065
doi: 10.1111/jvim.15756
pmc: PMC7255680
doi:
Substances chimiques
Anticonvulsants
0
Triglycerides
0
Types de publication
Clinical Trial, Veterinary
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1248-1259Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/P001874/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/P010881/1
Pays : United Kingdom
Organisme : German Federal Ministry of Education and Research
Organisme : Hans-Böckler Foundation
ID : PhD Scholarship
Organisme : American Kennel Club Canine Health Foundation
ID : Grant 2252
Informations de copyright
© 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Références
Epilepsia. 2017 Aug;58(8):1423-1429
pubmed: 28682459
J Anim Physiol Anim Nutr (Berl). 2002 Oct;86(9-10):306-12
pubmed: 12452972
Brain. 2016 Feb;139(Pt 2):431-43
pubmed: 26608744
J Vet Intern Med. 2015 Mar-Apr;29(2):614-9
pubmed: 25711374
Vet Clin North Am Small Anim Pract. 2006 Sep;36(5):1107-27, vii
pubmed: 16984829
PLoS One. 2018 Feb 8;13(2):e0192182
pubmed: 29420639
Mol Pharmacol. 1997 Mar;51(3):363-9
pubmed: 9058589
Acta Neurol Scand. 2015 Mar;131(3):187-90
pubmed: 25312999
Vet Rec. 2013 Mar 30;172(13):338
pubmed: 23300065
Neurobiol Dis. 2016 Dec;96:38-46
pubmed: 27546058
Cochrane Database Syst Rev. 2016 Feb 09;2:CD001903
pubmed: 26859528
Front Behav Neurosci. 2018 Feb 22;12:29
pubmed: 29520223
J Vet Intern Med. 2015 Nov-Dec;29(6):1564-8
pubmed: 26500168
Neuropharmacology. 2013 Jun;69:105-14
pubmed: 23177536
Am J Vet Res. 2009 May;70(5):614-8
pubmed: 19405900
Biochem J. 1992 Feb 1;281 ( Pt 3):577-92
pubmed: 1536639
Clin Tech Small Anim Pract. 1998 Aug;13(3):185-92
pubmed: 9775509
Biochem Soc Trans. 2018 Feb 19;46(1):183-196
pubmed: 29432141
Neurology. 2012 May 15;78(20):1548-54
pubmed: 22573629
BMC Vet Res. 2018 Mar 2;14(1):64
pubmed: 29499762
Curr Treat Options Neurol. 2008 Nov;10(6):410-9
pubmed: 18990309
J Vet Pharmacol Ther. 2014 Oct;37(5):421-34
pubmed: 24611573
Epilepsia Open. 2019 Feb 14;4(1):193-199
pubmed: 30868131
Epilepsy Res. 2017 Jul;133:6-9
pubmed: 28395176
Vet J. 2014 Dec;202(3):471-6
pubmed: 25457266
Epilepsy Behav. 2013 Jun;27(3):508-9
pubmed: 23619429
Neuropharmacology. 2015 Dec;99:500-9
pubmed: 26256422
Epilepsy Curr. 2008 Sep-Oct;8(5):127-30
pubmed: 18852835
BMC Vet Res. 2014 Oct 22;10:257
pubmed: 25338624
Clin Chem. 1982 Apr;28(4 Pt 1):642-5
pubmed: 7074833
Nutr Res Rev. 2007 Dec;20(2):180-94
pubmed: 19079869
Curr Neuropharmacol. 2018;16(7):1059-1085
pubmed: 29046155
Res Vet Sci. 2018 Aug;119:276-284
pubmed: 30064067
J Am Vet Med Assoc. 1996 Jan 15;208(2):234-6
pubmed: 8567379
Acta Biochim Pol. 2000;47(4):1093-105
pubmed: 11996099
J Small Anim Pract. 2014 Feb;55(2):108-11
pubmed: 24433448
J S Afr Vet Assoc. 1990 Sep;61(3):86-9
pubmed: 2287006
J Vet Intern Med. 2018 Sep;32(5):1665-1676
pubmed: 30216557
Br J Nutr. 2018 Sep;120(5):484-490
pubmed: 30001753
J Vet Intern Med. 1993 Sep-Oct;7(5):318-27
pubmed: 8263851
Epilepsy Behav. 2011 Jun;21(2):160-7
pubmed: 21531631
Vet Rec. 2015 Feb 21;176(8):203
pubmed: 25564473
Dis Model Mech. 2012 Jan;5(1):115-24
pubmed: 21876211
Clin Trials. 2007;4(4):350-6
pubmed: 17848496
J Neurochem. 2014 May;129(3):426-33
pubmed: 24383952
FEBS J. 2011 Jan;278(2):182-94
pubmed: 21156023
J Vet Intern Med. 2015 Jul-Aug;29(4):1081-7
pubmed: 25945683
Vet Rec. 2018 Jun 2;182(22):633
pubmed: 29700175
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
J Am Vet Med Assoc. 2000 Jul 15;217(2):200-4
pubmed: 10909458
Curr Opin Neurol. 2017 Apr;30(2):187-192
pubmed: 28141738
PLoS One. 2012;7(11):e49510
pubmed: 23145181
Vet Rec. 2009 Nov 7;165(19):556-8
pubmed: 19897869
BMC Vet Res. 2019 May 30;15(1):181
pubmed: 31146740
Brain Res. 2009 Nov 3;1296:117-26
pubmed: 19703432
Epilepsy Behav. 2016 Feb;55:62-8
pubmed: 26773515
Epilepsia. 2018 Nov;59(11):e172-e178
pubmed: 30324610
J Am Vet Med Assoc. 2014 Sep 1;245(5):504-8
pubmed: 25148091
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:110-6
pubmed: 25445478
J Vet Intern Med. 2017 Jul;31(4):1123-1131
pubmed: 28703446
Neuroscience. 2018 Aug 21;386:315-325
pubmed: 29966721
J Am Vet Med Assoc. 2000 Sep 15;217(6):847-52
pubmed: 10997154
BMC Vet Res. 2015 Aug 28;11:176
pubmed: 26316233
J Small Anim Pract. 1999 Jan;40(1):11-5
pubmed: 10092036
Food Chem Toxicol. 2009 Jan;47(1):35-9
pubmed: 19135768
Epilepsy Behav. 2014 Mar;32:27-8
pubmed: 24463305
J Vet Intern Med. 2018 Mar;32(2):775-781
pubmed: 29424456
Pharmacol Ther. 2000 Feb;85(2):77-85
pubmed: 10722121
BMC Vet Res. 2016 May 21;12:79
pubmed: 27206489
Exp Ther Med. 2017 Jul;14(1):765-770
pubmed: 28672997
Vet Rec. 2016 Sep 3;179(9):229
pubmed: 27329504
Vet Rec. 2016 Dec 3;179(22):573
pubmed: 27784836
BMC Vet Res. 2015 Aug 28;11:182
pubmed: 26316133
Br J Nutr. 2015 Nov 14;114(9):1438-47
pubmed: 26337751
BMC Vet Res. 2017 Apr 7;13(1):90
pubmed: 28388948
Epilepsy Behav. 2009 Aug;15(4):527-8
pubmed: 19541544
BMC Vet Res. 2015 Aug 28;11:148
pubmed: 26316175
J Pharmacol Exp Ther. 2015 Jan;352(1):43-52
pubmed: 25326131
Nutr Clin Pract. 2015 Feb;30(1):100-3
pubmed: 25112945
Amino Acids. 2017 Jan;49(1):1-20
pubmed: 27683025
Lancet Neurol. 2018 Jan;17(1):84-93
pubmed: 29263011
Vet Rec Open. 2016 Jun 20;3(1):e000174
pubmed: 27403328
J Vet Intern Med. 2014 Mar-Apr;28(2):510-4
pubmed: 24612035
Neurochem Res. 2017 Jan;42(1):35-49
pubmed: 27826689
J Vet Intern Med. 2020 May;34(3):1248-1259
pubmed: 32293065
Top Companion Anim Med. 2013 May;28(2):67-71
pubmed: 24070684
Vet Rec. 2016 Jun 25;178(26):650-1
pubmed: 27339925
Vet J. 2012 Mar;191(3):396-8
pubmed: 21641244